KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Convertible Debt (2019 - 2022)

Inovio Pharmaceuticals (INO) has disclosed Convertible Debt for 4 consecutive years, with $16.6 million as the latest value for Q4 2022.

  • Quarterly Convertible Debt rose 11.06% to $16.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $16.6 million through Dec 2022, up 11.06% year-over-year, with the annual reading at $16.6 million for FY2022, 11.06% up from the prior year.
  • Convertible Debt hit $16.6 million in Q4 2022 for Inovio Pharmaceuticals, up from $16.3 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $65.8 million in Q2 2020 to a low of $12.8 million in Q4 2019.
  • Historically, Convertible Debt has averaged $30.3 million across 4 years, with a median of $16.4 million in 2022.
  • Biggest five-year swings in Convertible Debt: tumbled 70.77% in 2021 and later grew 12.58% in 2022.
  • Year by year, Convertible Debt stood at $12.8 million in 2019, then grew by 10.1% to $14.1 million in 2020, then increased by 5.8% to $15.0 million in 2021, then grew by 11.06% to $16.6 million in 2022.
  • Business Quant data shows Convertible Debt for INO at $16.6 million in Q4 2022, $16.3 million in Q3 2022, and $16.5 million in Q2 2022.